<DOC>
	<DOCNO>NCT01045642</DOCNO>
	<brief_summary>An open label , balance , randomize , two-treatment , two-period , two-sequence , single dose , crossover oral bioequivalence study Omeprazole Magnesium 20 mg DR Capsules Dr. Reddy 's Laboratories Limited , India Prilosec OTCTM 20 mg ( Omeprazole Magnesium DR Tablets ) Procter Gamble , Cincinnati , Sweden 38 healthy , adult , human subject fast condition .</brief_summary>
	<brief_title>Bioequivalence Study Omeprazole Magnesium 20 mg DR Capsules Under Fasting Conditions</brief_title>
	<detailed_description>All study relate procedure , restriction , duration , date timing , information study formulation confidentiality subject data explain clearly volunteer clinical personnel time obtain informed consent . Volunteers sign consent form show '' willingness participate study enrol . Volunteers satisfy inclusion exclusion criterion find healthy physical examination laboratory investigation value within reference limit consider eligible admit study .</detailed_description>
	<mesh_term>Omeprazole</mesh_term>
	<criteria>Subjects provide write informed consent . Subjects healthy adult within 1845 year age ( inclusive ) . Body mass index ≥ 18 kg/m2 ≤ 25 kglm2 body weight less 50 kg . Subjects normal health determine medical history physical examination perform within 15 day prior dose PeriodI . Had normal ECG , Chest Xray vital sign . Availability subject entire study period willingness adhere protocol requirement evidence write informed consent . If subject female volunteer child bear potential practicing acceptable method birth control duration study judge investigator ( ) , condom , foam , jelly , diaphragm , intrauterine device ( IUD ) , abstinence , postmenopausal least 1 year , surgically sterile ( bilateral tubal ligation , bilateral oophorectomy , hysterectomy perform subject ) Each female subject give urine pregnancy test checkin periodI , periodII post study . Subjects incapable understanding informed consent . Subjects BP≤90/60 mrn/Hg BP≥140/90 mrn/Hg History hypersensitivity idiosyncratic reaction Omeprazole related drug . Any evidence impairment renal , hepatic , cardiac , lung gastrointestinal function . Subjects history tuberculosis , epilepsy , asthma ( past 5 year ) , diabetes , psychosis glaucoma eligible study Regular smoker smoke ten cigarette daily difficulty abstain smoke duration study period . Subjects take counter prescribed medication , include enzyme modifying drug systemic medication within past 30 day prior dose Period1 . History psychiatric illness , may impair ability provide write , informed consent . Subjects history alcohol substance abuse within last 5 year Subjects clinically significant abnormal value laboratory parameter . Subjects participate clinical investigation use experimental drug bleed 350 mL past 3 month . Subjects use drug substance know strong inhibitor CYP enzyme ( formerly know cytochrome P450 enzyme ) within 28 day prior first dose . Subjects use drug substance know strong inducer CYP enzyme ( formerly know cytochrome P450 enzyme ) within 28 day prior first dose . Subjects unable likely noncompliant protocol requirement restriction . Any subject Omeprazole contraindicate medical reason Subjects intolerant venipuncture Subjects positive urine screen drug abuse . All subject urine sample assay presence drug abuse part clinical laboratory screening procedure study period checkin . Subjects found urine concentration test drug allow participate Female volunteer use implant injected hormonal contraceptive anytime 6 month prior study use hormonal contraceptive within 14 day dose Female volunteer demonstrate positive pregnancy screen . All female subject screen pregnancy checkin study period . Subjects positive inconclusive result withdraw study Female volunteer currently breast feed . Female subject pregnant , breastfeeding , likely become pregnant study allow participate . Female subject child bear potential must either abstain sexual intercourse use reliable barrier method ( e.g . condom , IUD ) contraception course study ( first dose last blood collection ) allow participate</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>45 Years</maximum_age>
	<verification_date>January 2010</verification_date>
	<keyword>Bioequivalence</keyword>
	<keyword>Omeprazole</keyword>
	<keyword>Crossover</keyword>
</DOC>